Complement C3a Activates Astrocytes to Promote Medulloblastoma Progression Through TNF-α

Biao Gong,Duancheng Guo,Chaonan Zheng,Zhen Ma,Jie Zhang,Yanghui Qu,Xinhua Li,Gen Li,Li Zhang,Yuan Wang

DOI: https://doi.org/10.21203/rs.3.rs-850485/v1

2021-01-01

Abstract:Background: Medulloblastoma (MB) is the most common malignant brain tumor in children. Approximately one-third of MB patients remain incurable. Understanding the molecular mechanism of MB tumorigenesis is, therefore, critical for developing specific and effective treatment strategies. Our previous work demonstrated that astrocytes constitute the tumor microenvironment (TME) of MB and play an indispensable role in MB progression. However, the underlying mechanisms by which astrocytes are regulated and activated to promote MB remain elusive. Methods: By taking advantage of Math1-Cre/Ptch1(loxp/loxp) mice, which spontaneously develop MB, primary MB cells and astrocytes were isolated and then subjected to administration and coculture in vitro. Immunohistochemistry was utilized to determine the presence of C3a in MB sections. MB cell proliferation was evaluated by immunofluorescent staining. GFAP and cytokine expression levels in C3a-stimulated astrocytes were assessed by immunofluorescent staining, western blotting, q-PCR and ELISA. C3a receptor and TNF-alpha receptor expression was determined by PCR and immunofluorescent staining. p38 MAPK pathway activation was detected by western blotting. Transplanted MB mice were treated with a C3a receptor antagonist or TNF-alpha receptor antagonist to investigate their role in MB progression in vivo. Results: We found that complement C3a, a fragment released from intact complement C3 following complement activation, was enriched in both human and murine MB tumor tissue, and its receptor was highly expressed on tumor-associated astrocytes (TAAs). We demonstrated that C3a activated astrocytes and promoted MB cell proliferation via the p38 MAPK pathway. Moreover, we discovered that C3a upregulated the production of proinflammatory cytokines, such as IL-6 and TNF-alpha in astrocytes. Application of the conditioned medium of C3a-stimulated astrocytes promoted MB cell proliferation, which was abolished by preincubation with a TNF-alpha receptor antagonist, indicating a TNF-alpha-dependent event. Indeed, we further demonstrated that administration of a selective C3a receptor or TNF-alpha receptor antagonist to mice subcutaneously transplanted with MB suppressed tumor progression in vivo. Conclusions: C3a was released during MB development. C3a triggered astrocyte activation and TNF-alpha production via the p38 pathway, which promoted MB cell proliferation. Our findings revealed the novel role of C3a-mediated TNF-alpha production by astrocytes in MB progression. These findings imply that targeting C3a and TNF-alpha may represent a potential novel therapeutic approach for human MB.